 "Caplin Point hits record high on Brazil's Anvisa nod for Chennai unit")
Shares of Caplin Point Laboratories has moved higher by 12% to Rs 1,539 on the BSE after the pharmaceutical company announced that it got Brazil's Anvisa approval for sterile injectable site.
“The company has received approval from Brazil’s National Health Surveillance Agency Anvisa (Agencia Nacional de Vigilancia Sanitaria) for its sterile injectable manufacturing site at Chennai,” Caplin Point Laboratories said in a press release.
The approval grants access to the company to register and market its products at the large and growing Brazilian pharmaceutical market, it added.
"The facility is capable of manufacturing liquid injectables in Vials, Ampoules, Lyophilized Vials and Opthalmic dosages, was also recently approved by EU-GMP in July" it added.
The hit a record high of Rs 1,556 on the BSE after the announcements. Till 01:02 PM, a combined 129,028 shares changed hands on the counter on the BSE and NSE.
“The company has received approval from Brazil’s National Health Surveillance Agency Anvisa (Agencia Nacional de Vigilancia Sanitaria) for its sterile injectable manufacturing site at Chennai,” Caplin Point Laboratories said in a press release.
The approval grants access to the company to register and market its products at the large and growing Brazilian pharmaceutical market, it added.
"The facility is capable of manufacturing liquid injectables in Vials, Ampoules, Lyophilized Vials and Opthalmic dosages, was also recently approved by EU-GMP in July" it added.
The hit a record high of Rs 1,556 on the BSE after the announcements. Till 01:02 PM, a combined 129,028 shares changed hands on the counter on the BSE and NSE.